Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5

Two hypomethylating agents (HMAs), azacitidine and decitabine, have demonstrated clinical activities in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML); however, potential problems include development of acquired resistance. HMA-resistant patients have very poor prognosis and this co...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Hur, Eun-Hye, Jung, Seung-Hyun, Goo, Bon-Kwan, Moon, Juhyun, Choi, Yunsuk, Choi, Dae Ro, Chung, Yeun-Jun, Lee, Je-Hwan
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2016
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355301/
https://ncbi.nlm.nih.gov/pubmed/28052028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14342
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires